SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received a De Novo approval by the U.S. Food and Drug ...
Please provide your email address to receive an email when new articles are posted on . AI module for the detection of hypertrophic cardiomyopathy gains de vovo FDA approval. The module is integrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results